Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BioCryst Pharma Raises FY2025 Sales Guidance from $580.000M-$600.000M to $590.000M-$600.000M vs $625.558M Est

Author: Benzinga Newsdesk | November 03, 2025 07:01am
BioCryst Pharma (NASDAQ:BCRX) raises FY2025 sales outlook from $580.000 million-$600.000 million to $590.000 million-$600.000 million vs $625.558 million estimate.

Posted In: BCRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist